PubRank

Albert S Baldwin

Author PubWeight™ 95.57‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 2003 4.18
2 NF-kappaB as a therapeutic target in cancer. Trends Mol Med 2002 3.08
3 Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. J Clin Invest 2007 2.99
4 Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK. Genes Dev 2008 2.89
5 Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002 2.88
6 Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov 2011 2.77
7 JNK potentiates TNF-stimulated necrosis by increasing the production of cytotoxic reactive oxygen species. Genes Dev 2004 2.51
8 Glycogen synthase kinase 3beta functions to specify gene-specific, NF-kappaB-dependent transcription. Mol Cell Biol 2005 2.18
9 Loss of epithelial RelA results in deregulated intestinal proliferative/apoptotic homeostasis and susceptibility to inflammation. J Immunol 2008 1.95
10 Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol Cell Biol 2004 1.79
11 Requirement of the NF-kappaB subunit p65/RelA for K-Ras-induced lung tumorigenesis. Cancer Res 2010 1.78
12 p85α SH2 domain phosphorylation by IKK promotes feedback inhibition of PI3K and Akt in response to cellular starvation. Mol Cell 2012 1.76
13 Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. Blood 2006 1.71
14 Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004 1.65
15 IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem 2006 1.57
16 Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer. Cancer Res 2008 1.51
17 Proteasome inhibition promotes regression of left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 2007 1.50
18 LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. Cancer Cell 2007 1.47
19 Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev 2005 1.42
20 NF-kappa B and I kappa B alpha are found in the mitochondria. Evidence for regulation of mitochondrial gene expression by NF-kappa B. J Biol Chem 2002 1.37
21 Proteasome inhibition ablates activation of NF-kappa B in myocardial reperfusion and reduces reperfusion injury. Am J Physiol Heart Circ Physiol 2002 1.37
22 Positive and negative regulation of EAAT2 by NF-kappaB: a role for N-myc in TNFalpha-controlled repression. EMBO J 2005 1.36
23 Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K/Akt pathway and of IkappaB kinase activity. Blood 2004 1.35
24 Elevated NF-kappaB activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. J Immunol 2002 1.35
25 Myocardin inhibits cellular proliferation by inhibiting NF-kappaB(p65)-dependent cell cycle progression. Proc Natl Acad Sci U S A 2008 1.35
26 Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by I kappa B kinase alpha. Cancer Res 2007 1.34
27 NF-kappaB mediates inhibition of mesenchymal cell differentiation through a posttranscriptional gene silencing mechanism. Genes Dev 2003 1.33
28 Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor κB and miR-221. J Biol Chem 2012 1.28
29 IKKalpha and IKKbeta each function to regulate NF-kappaB activation in the TNF-induced/canonical pathway. PLoS One 2010 1.22
30 Amelioration of chronic murine colitis by peptide-mediated transduction of the IkappaB kinase inhibitor NEMO binding domain peptide. J Immunol 2007 1.22
31 IkappaB kinase alpha and p65/RelA contribute to optimal epidermal growth factor-induced c-fos gene expression independent of IkappaBalpha degradation. J Biol Chem 2004 1.20
32 Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation. Cancer Res 2012 1.19
33 The nuclear factor kappaB subunits RelA/p65 and c-Rel potentiate but are not required for Ras-induced cellular transformation. Cancer Res 2004 1.19
34 Modular utilization of distal cis-regulatory elements controls Ifng gene expression in T cells activated by distinct stimuli. Immunity 2010 1.17
35 PTEN blocks tumor necrosis factor-induced NF-kappa B-dependent transcription by inhibiting the transactivation potential of the p65 subunit. J Biol Chem 2002 1.15
36 B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood 2012 1.15
37 Differential involvement of IkappaB kinases alpha and beta in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. J Immunol 2008 1.15
38 GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB. Cancer Discov 2013 1.13
39 Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol Med 2011 1.09
40 Potentiation of chemotherapeutic agents following antagonism of nuclear factor kappa B in human gliomas. J Neurooncol 2003 1.06
41 The kinases MSK1 and MSK2 are required for epidermal growth factor-induced, but not tumor necrosis factor-induced, histone H3 Ser10 phosphorylation. J Biol Chem 2006 1.05
42 Deletion of the NF-κB subunit p65/RelA in the hematopoietic compartment leads to defects in hematopoietic stem cell function. Blood 2013 1.02
43 Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma. Cancer Res 2012 1.01
44 Human polynucleotide phosphorylase (hPNPaseold-35): a potential link between aging and inflammation. Cancer Res 2004 1.01
45 Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin. PLoS One 2009 1.01
46 NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma. Clin Cancer Res 2011 1.00
47 Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia. PLoS One 2013 0.99
48 Lipopolysaccharide inhibition of glucose production through the Toll-like receptor-4, myeloid differentiation factor 88, and nuclear factor kappa b pathway. Hepatology 2009 0.96
49 IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. Mol Cancer Ther 2008 0.96
50 Dihydroartemisinin ameliorates inflammatory disease by its reciprocal effects on Th and regulatory T cell function via modulating the mammalian target of rapamycin pathway. J Immunol 2012 0.95
51 NF-kB and Bcl-3 activation are prognostic in metastatic colorectal cancer. Oncology 2010 0.95
52 Development of a high-throughput assay for identifying inhibitors of TBK1 and IKKε. PLoS One 2012 0.95
53 Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin. Mol Cancer Ther 2008 0.94
54 Loss of Arp2/3 induces an NF-κB-dependent, nonautonomous effect on chemotactic signaling. J Cell Biol 2013 0.93
55 Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas. Oncology 2007 0.92
56 Wound-induced p38MAPK-dependent histone H3 phosphorylation correlates with increased COX-2 expression in enterocytes. J Cell Physiol 2006 0.91
57 NF-kappa B hyperactivation has differential effects on the APC function of nonobese diabetic mouse macrophages. J Immunol 2003 0.89
58 MDA-9/syntenin is a key regulator of glioma pathogenesis. Neuro Oncol 2013 0.88
59 NF-kappaB pathways in the immune system: control of the germinal center reaction. Immunol Res 2008 0.86
60 C/EBPα, C/EBPα oncoproteins, or C/EBPβ preferentially bind NF-κB p50 compared with p65, focusing therapeutic targeting on the C/EBP:p50 interaction. Mol Cancer Res 2011 0.85
61 Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine. Cancer Biol Ther 2013 0.85
62 Dendritic cells from lupus-prone mice are defective in repressing immunoglobulin secretion. J Immunol 2007 0.85
63 Monoallelic deletion of NFKBIA in glioblastoma: when less is more. Cancer Cell 2011 0.84
64 Essential role for epidermal growth factor receptor in glutamate receptor signaling to NF-kappaB. Mol Cell Biol 2008 0.83
65 Inhibitory kappa B kinase-beta is a target for specific nuclear factor kappa B-mediated delayed cardioprotection. J Thorac Cardiovasc Surg 2008 0.83
66 Observing single cell NF-κB dynamics under stimulant concentration gradient. Anal Chem 2012 0.82
67 Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. Cancer Res 2009 0.81
68 Oncoprotein suppression of tumor necrosis factor-induced NF kappa B activation is independent of Raf-controlled pathways. J Biol Chem 2003 0.79
69 Nuclear factor κ-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy. Int J Radiat Oncol Biol Phys 2010 0.79
70 Nuclear factor-kappaB activation in endothelium by Chlamydia pneumoniae without active infection. J Infect Dis 2003 0.78
71 Retinoic acid modulates chromatin to potentiate tumor necrosis factor alpha signaling on the DIF2 promoter. Nucleic Acids Res 2007 0.78
72 Regulation of NF-kappaB by oncoproteins and tumor suppressor proteins. Methods Mol Biol 2003 0.76
73 Altered T-cell entry and egress in the absence of Coronin 1A attenuates murine acute graft versus host disease. Eur J Immunol 2014 0.75
74 Using RNA interference in lung cancer cells to target the IKK-NF-κB pathway. Methods Mol Biol 2015 0.75